Clinical Trial Update: Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docosahexaenoic acid (DHA) in breast cancer survivors has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Breast Neoplasm
• Breast Cancer
• Ductal Carcinoma in Situ
• Invasive Breast Cancer
• Lobular Carcinoma in Situ
• Paget Disease of the Breast
• Stage Iiia Breast Cancer
• Stage Iiib Breast Cancer
• Stage Iiic Breast Cancer

Drugs mentioned

• Docosahexaenoic acid (DHA) (docosahexaenoic acid)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ | Phase 2 | Status: COMPLETED | Results posted: 2021-12-28